CHINA PHARMA HOLDINGS, INC. (CPHI) Form 10-Q — Aug 14, 2026
China Pharma Holdings (CPHI) reported Q2 2026 revenue of $0.95 million, down about 7.5% year over year, with the net loss widening to $1.46 million from $0.53 million a year earlier. For the six months ended June 30, 2026, revenue fell 10.7% to $1.93 million and the net loss more than doubled to $2.60 million, as products that have not passed China's generic-drug consistency evaluation were excluded from centralized procurement programs. The quarterly report carries going-concern warnings: the company held just $0.3 million in cash against a $5.7 million working-capital deficit and a $49.8 million accumulated deficit at June 30, 2026.
Key figures
- Revenue
- 1931876
- Revenue Yoy
- -10.7% (six months); -7.5% (Q2)
- Cash Position
- 304874
- Shares Outstanding
- 43022002
- Q2 revenue
- 948340
- Q2 ga expense
- 1376974
- Q2 gross margin
- 8.8%
- Q2 gross profit
- 83566
- Accumulated deficit
- 49815506
- Ar 180 365 days pct
- 48.71% of receivables at June 30, 2026 vs 24.61% at Dec 31, 2025
- Reverse split ratio
- 1-for-10 (effective April 15, 2025)
- Prc nol carryforwards
- approximately $31.7 million
- Collateral pledged ppne
- 3228728
- Working capital deficit
- current liabilities exceed current assets by $5.7 million
- Related party ceo advances
- 1593929
- Stock issued for intangibles
- 14994000
- Subsequent pipe net proceeds
- 4425000
- Subsequent pipe gross proceeds
- 5000000
Price after filing
Close on the filing date to close N calendar days later (from $1.13). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.